Nuo Therapeutics, Inc.

Equities

AURX

US67059V2097

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 14:47:40 2024-05-31 EDT			5-day change	1st Jan Change
0.7499 ^USD	-0.01%		-3.86%	+36.35%

05-20	Nuo Therapeutics, Inc. announced that it has received $0.650875 million in funding	CI
05-15	Nuo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Nuo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018

April 16, 2019 at 05:27 pm

Nuo Therapeutics, Inc. announced earnings results for the full year ended December 31, 2018. For the full year, the company announced total revenue was USD 1.370 million compared to USD 721,045 a year ago. Net loss was USD 1.541 million compared to USD 14.978 million a year ago. Basic loss per share was USD 0.07 compared to USD 1.02 a year ago.

Latest news about Nuo Therapeutics, Inc.

Nuo Therapeutics, Inc. announced that it has received $0.650875 million in funding	05-19	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Nuo Therapeutics, Inc. announced that it expects to receive $0.650875 million in funding	05-09	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-19	CI
Exor-backed NUO invests in Italian teenage clothing chain Subdued	03-19	RE
Nuo Therapeutics, Inc. announced that it has received $0.9625 million in funding	12-18	CI
Nuo Therapeutics, Inc. announced that it expects to receive $0.9625 million in funding	12-07	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-20	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Insider Buy: Nuo Therapeutics	23-08-04	MT
Nuo Therapeutics, Inc. announced that it has received $1.035 million in funding	23-07-31	CI
Nuo Therapeutics, Inc. announced that it expects to receive $1.035 million in funding	23-07-25	CI
Nuo Therapeutics Selects to Exhibit AurixÂ® System At Vizient Innovative Technology Exchange	23-06-26	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
Nuo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	23-04-16	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-04	CI
Nuo Therapeutics, Inc. announced that it expects to receive $0.5 million in funding from Pacific Medical, Inc.	22-08-23	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-08	CI
Nuo Therapeutics, Inc. Enters into an Exclusive Sales Agent and Services Agreement with Pacific Medical, Inc	22-06-28	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Insider Buy: Nuo Therapeutics	22-05-02	MT
Nuo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
Nuo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	22-04-14	CI
Nuo Therapeutics, Inc. announced that it expects to receive $3.55 million in funding	22-04-10	CI

Chart Nuo Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Nuo Therapeutics, Inc. is a commercial stage medical device company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's product, Aurix, is a biodynamic hematogel that uses a patient's own platelets and plasma as a catalyst for healing. Its commercial offering consists of point of care technology for the separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. This offering is known as Aurix or the Aurix System. The Aurix System produces a platelet rich plasma (PRP) gel at the point of care using the patient's own platelets and plasma sourced from a small draw of peripheral blood. Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NUO THERAPEUTICS, INC.	+36.35%	33.18M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs